The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Compounding involves preparing drugs in forms that are different from the generic prescription standard. This may include altering the strength, ingredients, or dosage form. Compounding is a way to create custom drugs for patients who may not be able to take the medication in its standard form, such as due to an allergy or difficulty swallowing. Compounding is necessary for these patients to still be able to properly get the prescriptions they need. One area of compounding is preparing drugs in new dosage forms. For example, if a drug manufacturer only provides a drug as a tablet, a compounding pharmacist might make a medicated lollipop that contains the drug. Patients who have difficulty swallowing the tablet may prefer to suck the medicated lollipop instead. Another form of compounding is by mixing different strengths (g, mg, mcg) of capsules or tablets to yield the desired amount of medication indicated by the physician, physician assistant, nurse practitioner, or clinical pharmacist practitioner. This form of compounding is found at community or hospital pharmacies or in-home administration therapy. Compounding pharmacies specialize in compounding, although many also dispense the same non-compounded drugs that patients can obtain from community pharmacies.
The sponsor and the local site investigators are jointly responsible for writing a site-specific informed consent that accurately informs the potential subjects of the true risks and potential benefits of participating in the study, while at the same time presenting the material as briefly as possible and in ordinary language. FDA regulations state that participating in clinical trials is voluntary, with the subject having the right not to participate or to end participation at any time.
== History == Clocinnamox was first described in the scientific literature by 1992. Methoclocinnamox, which is metabolically converted into clocinnamox and is a μ-opioid receptor partial agonist, was first described by 1995. Methocinnamox was first described in 2000.
== Clinical studies == A C-SALVAGE Phase 2 trial on safety and efficacy was reported in 2015. One randomized, open-label study was done on patients that had previous failure of a ribavirin/peginterferon treatment. SVR24 occurred in 96% of the patients with only 3 individuals relapsing. Additional phase II trials were examined under the names: C-SWIFT, C-WORTHY, and C-WORTHY Coinfection. The first trial studied shorter dosing periods of 4, 6, or 8 weeks. C-SWIFT showed that the longer the time of treatment, the better the SVR results among patients. The C-WORTHY study combined elbasvir with grazoprevir and additionally ribavirin in cases of cirrhosis. This demographic of patients is the most treatment refractory and the study showed that the ribavirin did not improve effects. The C-WORTHY Coinfection trial studied patients with HCV and HIV. Treatments of monoinfected patients and coinfected patients resulted in better SRV12 for the patients with coinfection and treated with ribrivin, too, at 97%. Phase III study results of the drug were released in 2016. Results from the C-EDGE IBLD trial show high rates of sustained virological response (SVR) after the completion of the prescribed treatment. This was examined 12-weeks after (SRV12). Safety profiles were consistent with previous studies. This study was a randomized, double-blind and placebo-controlled. 93% of the patients included in these studies showed SVR12 and had been cured of the virus. The C-EDGE CO-STAR trial showed high SVR after 24-weeks. This study reaffirmed results from studies of the previous year.
Etoetonitazene is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is an analogue of etonitazene where the ethoxy sidechain has been extended to ethoxyethoxy. It is less potent than other benzimidazole class opioids, but is still a potent mu opioid receptor agonist with around 50x the potency of morphine, and has been sold as a designer drug since around 2022.
Sources: en.wikipedia.org
Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. Its name is derived from poly- 'many', myos- 'muscle' and -itis 'inflammation'. The inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles.
=== Non-cardiac conditions === The distinction between cardiac and non-cardiac conditions is somewhat artificial; the conditions listed below are not primary heart diseases, but they exert indirect effects on the heart muscle. Other conditions that directly or indirectly lead to heart muscle damage and death can also increase troponin levels, such as kidney failure. Cardiac troponins are increased in around 40% of patients with critical illnesses such as sepsis. There is an increased risk of mortality and length of stay in the intensive-care unit in these patients. In severe gastrointestinal bleeding, there can also be a mismatch between oxygen demand and supply of the myocardium.
According to US State Department Spokesperson, Jen Psaki : "US law exempts foreign government officials, including heads of state and heads of government from certain potential inadmissibility grounds". The visa refusal came after some Indian-American groups and human rights organizations with political view campaigned against Modi, including the Coalition Against Genocide. On June 11, 2014, Robert Blackwill, the former Coordinator for Strategic Planning and Deputy US National Security Advisor during the presidency of George W. Bush, spoke at length about India–U.S. relations and said : "Mr Modi is a determined leader. He is candid and frank. I also worked with him during the Gujarat earthquake when I was posted as (the US) ambassador to India. ... It was mistake by the current Obama administration to delay engagement with Mr Modi. I do not know why they did so but definitely, this did not help in building relationship. ... The old formula and stereotypes will not work if the US administration wants to engage with Mr Modi. The Indian prime minister is candid, direct and smart. He speaks his mind. The US administration also has to engage in candid conversation when Mr Modi meets President Obama later this year. They have to do something innovative to engage with him." Nicholas Burns, former U.S.
== Treatment == The options for kidney replacement therapy are severely limited in cats, as kidney transplants and hemodialysis in veterinary medicine are only carried out in exceptional cases due to the high equipment, logistical and financial costs involved. The aim is therefore to detect chronic kidney disease at the earliest possible stage, when the kidneys still have sufficient reserve capacity. At the same time, attempts are made to reduce the amount of urinary substances—especially nitrogen compounds and phosphate—in the diet by means of dietary measures. Finally, metabolic imbalances and sequelae must be buffered. From a plasma creatinine level of 7 mg/dL (618.8 μmol/L), however, drug therapy is not very promising.
Sources: en.wikipedia.org
Elam came under the domination of Akkad in the time of Sargon though it remained restive. The 2nd ruler of Akkad, Rimush, campaigned there afterward adding "conqueror of Elam and Parahsum" to his royal titulary. The 3rd ruler, Manishtushu, conquered the city of Anshan in Elam and also the city of Pashime, installing imperial governors in those places. Naram-Sin added "commander of all the land of Elam, as far as Parahsum," to his royal titulary. During his rule, "military governors of the country of Elam" (shakkanakkus) with typically Akkadian names are known, such as Ili-ishmani or Epirmupi. This suggests that these governors of Elam were officials of the Akkadian Empire. Naram-Sin exercised great influence over Susa during his reign, building temples and establishing inscriptions in his name, and having the Akkadian language replace Elamite in official documents.
== Early life == Princess Zita of Bourbon-Parma was born at the Villa Pianore in the Italian Province of Lucca, 9 May 1892. The unusual name Zita was given to her after Zita, a popular Italian saint who had lived in Tuscany in the 13th century. She was the third daughter and fifth child of the deposed Robert I, Duke of Parma, and his second wife, Infanta Maria Antonia of Portugal, a daughter of King Miguel of Portugal and his wife Adelaide of Löwenstein-Wertheim-Rosenberg. Zita's father had lost his throne as a result of the movement for Italian unification in 1859 when he was still a child. He fathered twelve children during his first marriage to Princess Maria Pia of the Two Sicilies (six of whom were mentally disabled, and three of whom died young). Duke Robert became a widower in 1882, and two years later he married Infanta Maria Antonia of Portugal. The second marriage produced a further twelve children. Zita was the 17th among Duke Robert's 24 children. Robert moved his large family between Villa Pianore (a large property located between Pietrasanta and Viareggio) and his Schwarzau Castle in Lower Austria. It was mainly in these two residences that Zita spent her formative years. The family spent most of the year in Austria, moving to Pianore in the winter and returning in the summer. To move between them, they took a special train with sixteen coaches to accommodate the family and their belongings.
In medieval Europe, early Christian monasteries adopted Roman aquacultural practices. Aquaculture spread because people away from coasts and big rivers were otherwise dependent on fish which required salting in order to be preserved. Fish was an important food source in medieval Europe, when in average 150 days per year were days of fasting and abstinence, and meat was prohibited. Improvements in transportation during the 19th century made fresh fish easily available and inexpensive, even in inland areas, rendering aquaculture less popular. The 15th-century fishponds of the Trebon Basin in the present-day Czech Republic are maintained as a tentative UNESCO World Heritage Site. Samoans practised "a traditional form of giant clam ranching". Hawaiians constructed oceanic fish ponds. A remarkable example is the "Menehune" fishpond dating from at least 1,000 years ago, at Alekoko. Legend records its construction by the mythical Menehune dwarf-people. In the first half of the 18th century, German Stephan Ludwig Jacobi experimented with external fertilization of brown trout and salmon. He wrote an article "Von der künstlichen Erzeugung der Forellen und Lachse" (On the Artificial Production of Trout and Salmon) summarizing his findings, and earning him a reputation as the founder of artificial fish-rearing. By the latter decades of the 18th century, oyster-farming had begun in estuaries along the Atlantic Coast of North America. The word "aquaculture" appeared in an 1855 newspaper article in reference to the harvesting of ice.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.